Bristol-Myers Squibb seeks FDA biologics license for CAR T-cell therapy in advanced large B-cell lymphoma
Bristol-Myers Squibb has submitted a biologics license application to the FDA for the company’s investigational chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel, for the treatment of adults with relapsed or refectory large B-cell lymphoma who have received two previous lines of therapy.